- Conditions
- Autosomal Dominant Hypocalcemia
- Interventions
- Not listed
- Lead sponsor
- Calcilytix Therapeutics, Inc., a BridgeBio company
- Industry
- Eligibility
- Up to 90 Years
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 9
- States / cities
- Oakland, California • Aurora, Colorado • Jacksonville, Florida + 6 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–5
of 5
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Autosomal Dominant Hypocalcemia Type 1 (ADH1)
- Interventions
- Encaleret
- Drug
- Lead sponsor
- Calcilytix Therapeutics, Inc., a BridgeBio company
- Industry
- Eligibility
- 0 Years to 17 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 4
- States / cities
- New Haven, Connecticut • Washington D.C., District of Columbia • Jacksonville, Florida + 1 more
- Conditions
- Autosomal Dominant Hypocalcemia (ADH), Autosomal Dominant Hypocalcemia Type 1 (ADH1)
- Interventions
- Encaleret
- Drug
- Lead sponsor
- Calcilytix Therapeutics, Inc., a BridgeBio company
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Hypoparathyroidism, Hypocalcemia, Autoimmune Polyendocrine Syndrome Type 1, Autosomal Dominant Hypocalcemia Type 1 (ADH1)
- Interventions
- Synthetic Human Parathyroid Hormone 1-34 pump
- Drug
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- 7 Years to 70 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Autosomal Dominant Hypocalcemia (ADH)
- Interventions
- Encaleret, Standard of Care
- Drug · Dietary Supplement
- Lead sponsor
- Calcilytix Therapeutics, Inc., a BridgeBio company
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 11
- States / cities
- Oakland, California • Aurora, Colorado • Indianapolis, Indiana + 8 more